Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.

10/22/2026, 4:45 PM • The Motley Fool

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

BioNTech faces mounting clinical setbacks in its cancer vaccine pipeline, including a halted Phase 2 trial for autogene cevumeran and BNT113's failure to meet a primary endpoint in head and neck cancer trials. With COVID-19 vaccine revenues declining sharply (down 60% YoY) and the company unprofitable, investors must weigh the deep pipeline potential against significant uncertainty. The stock is recommended only for risk-tolerant investors.

10/18/2026, 2:32 PM • The Motley Fool

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

BioNTech has 16.6 billion euros in cash and is advancing 14 pivotal oncology trials, positioning itself to transition from a COVID-19 vaccine maker to a major cancer treatment company. With a diversified pipeline including promising candidates like pumitamig and a $1 billion share repurchase program, the company has financial flexibility to fund development. However, risks include trial failures, declining COVID-19 revenue, and regulatory delays.

10/17/2026, 12:23 PM • The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

10/16/2026, 8:50 PM • The Motley Fool

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.

10/08/2026, 8:43 PM • The Motley Fool

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

09/30/2026, 4:54 AM • GlobeNewswire

Why Pfizer Stock Was so Healthy in August

Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.

09/08/2026, 4:34 PM • The Motley Fool

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

09/03/2026, 5:30 PM • The Motley Fool

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

09/03/2026, 1:00 PM • GlobeNewswire

Is BioNTech Stock a No-Brainer Buy on the Dip?

BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.

09/02/2026, 3:10 PM • The Motley Fool

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

08/26/2026, 9:46 AM • GlobeNewswire

$7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, Challenges

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

08/26/2026, 9:44 AM • GlobeNewswire

BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.

BioNTech has appointed Guido Oelkers, former CEO of Swedish rare-disease company Sobi, as its next chief executive, effective February 1, 2027. Oelkers will succeed co-founder Uğur Şahin as BioNTech transitions from a COVID vaccine-focused company to one with a diversified oncology pipeline. The appointment represents a planned transition rather than a strategic shift, with Oelkers' commercial and acquisition experience expected to guide the company through multiple product launches later this decade.

08/13/2026, 9:30 AM • The Motley Fool

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire

BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt

BioNTech will release second quarter 2026 financial results on August 4, 2026, followed by a conference call. The company will showcase progress across its late-stage oncology pipeline at ASCO 2026, including data on its PD-L1xVEGF-A bispecific pumitamig developed with Bristol Myers Squibb, which demonstrated encouraging efficacy in non-small cell lung cancer patients.

07/21/2026, 6:45 AM • GlobeNewswire